Advances in molecular genetic factors of relapse/refractory diffuse large B-cell lymphoma after first-line immunochemotherapy
Diffuse large B-cell lymphoma is a highly heterogeneous tumor with different clinical features,genetic changes,immunophenotypes,and responses to immunochemotherapy regimen.The first-line treatment with R-CHOP(rituximab+cyclophosphamide+doxorubicin+vinnestine+prednisone)can achieve a long survival in most patients with diffuse large B-cell lymphoma,but relapse/refractory would develop in 30％to 40％of patients.This paper reviews the research progress of the molecular typing of diffuse large B-cell lymphoma and the progress of relapse/refractory related gene mutations after first-line immunochemotherapy.
diffuse large B-cell lymphomaimmunochemotherapyrelapse/refractorymolecular genetics
NETL
NSTL
万方数据
